Metformin and Temozolomide, a synergic option to overcome resistance in glioblastoma multiforme models

Autor: Silvia Valtorta 1, 2, 3, 4, Alessia Lo Dico 5, Isabella Raccagni 1, Daniela Gaglio 2, Sara Belloli 2, Letterio S. Politi 6, 7, 8, Cristina Martelli 5, Cecilia Diceglie 5, 1, Marcella Bonanomi 4, Giulia Ercoli 9, Valentina Vaira 5, 9, Luisa Ottobrini 2, 5, Rosa Maria Moresco 1

Publikováno v: Oncotarget (2017).
info:cnr-pdr/source/autori:Silvia Valtorta 1,2,3,4,*, Alessia Lo Dico 5,*, Isabella Raccagni 1,2,3,4, Daniela Gaglio 2,4, Sara Belloli 2,3,4, Letterio S. Politi 6,7,8, Cristina Martelli 5, Cecilia Diceglie 5,1, Marcella Bonanomi 4, Giulia Ercoli 9, Valentina Vaira 5,9, Luisa Ottobrini 2,5,* and Rosa Maria Moresco 1,2,3,4,*/titolo:Metformin and Temozolomide, a synergic option to overcome resistance in glioblastoma multiforme models/doi:/rivista:Oncotarget/anno:2017/pagina_da:/pagina_a:/intervallo_pagine:/volume

Glioblastoma multiforme (GBM) is the most aggressive primary brain tumor with poor survival. Cytoreduction in association with radiotherapy and temozolomide (TMZ) is the standard therapy, but response is heterogeneous and life expectancy is limited.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=cnr_________::7ffbe54f58bfb27b307ca2d8e493dcce
https://publications.cnr.it/doc/379984